Of course your angst is welcome here! Where else? I was only having a bit of a jab about the J&J comparison, which is far-fetched in any case.
I personally don't find the PRs that horrid. The "story" is that the company has awesome potential in 2 distinct fields. The market manipulators have decided that the current version of the story is worth less than .35 a share, which makes CTUM the #2 winner in '07 for me.
I think DR is well aware of the fact that until he provides some degree of harder evidence about the commercial viability of LFG or LTC, all he has is a "story". The OTC and Pinkies are riddled with companies that have such "stories". Many grease up the PR machine regularly and leave a litany of bag holders in their wake.
I'm really glad you're going to the meeting. I'd love to be there myself, but as my $$ outlay is no where near yours, I doubt I'd even be allowed a question.
With regard to LandFill Gas, I'm finding it hard to accept that the benefits of a completed deal that proves the technology commercailly aren't worth some heavy concessions at the Chastang negotiating table. Let's face it- many companies are indeed NOW demonstrating working models of alternative energy production and will be ready to capitalise when the next US administration enacts carbon credit trading. It's very short-sighted to get hung up on one landfill, especially the protype, with so much in the balence over the next 3-8 years, and frankly, in spite of DR's reassurances that these set backs are mere "delays," I'm not completely convinced that this is the whole and total truth. I am convinced that a single PR that says there is a gas deal and the meter is ticking assures a PPS of over a buck forever.
I'd love to ask a question about the above topic and hear the response DR gives. I've emailed the company on numerous occasions to ask just that, but to date have received no response.
With LTC, DR seems to be making the right moves. Hiring a specialist to get the product to market, through the maze of regulatory hurdles, is a great idea for shareholders. Hopefully now DR can concentrate on a partnership with a big Med Co or insurance company to fund the trials.
What are your thoughts for how the PR should be handled?
News 
Market Data 
Discover 
